



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

Donald J. Bird  
Morgan Lewis & Bockius LLP  
1111 Pennsylvania Ave., NW  
Washington DC 20004

In Re: Patent Term Extension  
Application for  
U.S. Patent No. 4,911,932

MAR 20 2007

Dear Mr Bird :

A interim extension under 35 U.S.C. § 156(e)(2) is enclosed extending the term of U.S. Patent No. 4,911,932 for a period of 1 year. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from FDA's Electronic Forms Download Website:  
<http://www.fda.gov/opacom/morechoices/fdaforms/default.html>  
(<http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf>).

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail at [mary.till@uspto.gov](mailto:mary.till@uspto.gov).

Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Office of Regulatory Policy  
HFD-7  
5600 Fishers Lane (Rockwall II Rm 1101)  
Rockville, MD 20857

RE: VUSION™ Ointment  
FDA Docket No.:

Attention: Beverly Friedman

**UNITED STATES PATENT AND TRADEMARK OFFICE**


In re Johnson & Johnson Consumer Companies, Inc. :  
Request for Patent Term Extension : ORDER GRANTING  
U.S. Patent No. 4,911,932 : INTERIM EXTENSION

Johnson & Johnson Consumer Companies, Inc., the owner of record in the United States Patent and Trademark Office (USPTO) of U.S. Patent No. 4,911,932, filed an application for patent term extension under 35 U.S.C. § 156 on April 5, 2006. The original term of the patent is due to expire on March 27, 2007. The patent claims the human drug product VUSION™ Ointment, having the active ingredients miconazole nitrate, zinc oxide and white petrolatum, which was approved by the Food and Drug Administration for commercial marketing or use on February 15, 2006. An extension of 5 years is requested.

The initial USPTO review of the application to date indicates that the subject patent is eligible for extension of the patent term under 35 U.S.C. § 156. A final determination of the length of the extension of the patent term and issuance of a patent term extension certificate cannot be made until a final determination of the length of the regulatory review period is made. Because the original term of the patent would expire before a certificate of patent term extension can be issued, an interim extension of the patent term is appropriate.

An interim extension under 35 U.S.C. § 156(e)(2) of the term of U.S. Patent No. 4,911,932 is granted for a period of one year from the original expiration date of the patent.

3/15/07  
Date

  
\_\_\_\_\_  
Jon W. Dudas  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office